Dr. Hafkin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
PO Box 29750
Austin, TX 78755Phone+1 512-375-3485- Is this information wrong?
Education & Training
- The University of Texas Health Science Center at San AntonioClass of 1973
Certifications & Licensure
- TX State Medical License 1973 - 2019
- CA State Medical License 1977 - 2015
Clinical Trials
Publications & Presentations
PubMed
- 54 citationsAFN-1252, a FabI Inhibitor, Demonstrates a Staphylococcus-Specific Spectrum of ActivityJames A. Karlowsky, Nachum Kaplan, Barry Hafkin, Daryl J. Hoban, George G. Zhanel> ;Antimicrobial Agents and Chemotherapy. 2009 Aug 1
- 133 citationsWorldwide Assessment of Linezolid's Clinical Safety and Tolerability: Comparator-Controlled Phase III StudiesEthan Rubinstein, Raul E Isturiz, Harold C. Standiford, Leon G. Smith, Thomas H. Oliphant, Sue Cammarata, Barry Hafkin, Vu Le, Jack S. Remington> ;Antimicrobial Agents and Chemotherapy. 2003 Jun 1
- 310 citationsHematologic Effects of Linezolid: Summary of Clinical ExperienceStanton L. Gerson, Sheldon L. Kaplan, Jon B. Bruss, Vu Le, Felix M. Arellano, Barry Hafkin, David J. Kuter> ;Antimicrobial Agents and Chemotherapy. 2002 Aug 1
- Join now to see all
Press Mentions
- MicuRx Enrolls First Patient in a Phase 2 Clinical Trial in U.S. For Novel Antibiotic, Contezolid AcefosamilNovember 26th, 2018
- MicuRx Announces Receipt of FDA’s QIDP and Fast Track Designations for Contezolid and Contezolid AcefosamilSeptember 21st, 2018
- MicuRx Initiates Phase 1 Clinical Trial in U.S. For Novel Antibiotic Agent MRX-4November 30th, 2016
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: